不同预混型人胰岛素治疗老年2型糖尿病的疗效观察

目的探讨两种不同预混型人胰岛素治疗老年2型糖尿病的临床疗效及其安全性。方法将118例老年2型糖尿病患者随机分为观察组与对照组,各59例,观察组应用预混门冬胰岛素30(诺和锐30)治疗,而对照组应用预混人胰岛素30R(诺和灵30R)治疗,连续观察两个月,比较治疗前后两组患者空腹血糖、餐后2h血糖、糖化血红蛋白变化及低血糖发生情况。结果经治疗两组患者血糖及糖化血红蛋白均下降,观察组临床疗效明显优于对照组,两组餐后2h血糖及糖化血红蛋白比较差异有统计学意义(P<0.05);且观察组低血糖发生率为11.86%,明显低于对照组的27.12%,两组比较差异亦有统计学意义(P<0.05)。结论预混型人胰岛素治疗老年2型糖尿病安全有效,且预混门冬胰岛素30较预混人胰岛素30R降低血糖更显著。

Clinical efficacy and safety of two kinds of premixed human insulin preparations for treating elderly patients with type 2 diabetes

Objective To investigate the clinical efficacy and safety of two different types of premixed human insulin for treating elderly patients with type 2 diabetes. Methods One hundred and eighteen elderly patients with type 2 diabetes enrolled were randomly divided into the study group and the control group, each with 59 cases. The study group was treated with premixed insulin Aspart 30 (Aspart 30) for treatment, while the control group was given premixed insulin 30R (Novolin 30R) for treatment. The patients in the two groups were observed for two months. The fasting blood glucose, 2h postprandial blood glucose, glycated hemoglobin changes and the incidence of low blood glucose were compared between the two groups. Results After treatment, the blood glucose and glycated hemoglobin had decreased in both of the two groups. The clinical efficacy in the study group was better than that in the control group, and there were statistically significantly difference in 2h postprandial blood glucose and glycosylated hemoglobin between the two groups (P<0.05) The incidence of low blood glucose in the study group was 11.86%, significantly lower than 27.12% in the control group (P<0.05). Conclusion Premixed human insulin is safe and effective for treating elderly patients with type 2 diabetics, and premixed insulin Aspart 30 is more effective in blood glu- cose decreasing compared with premixed insulin Novolin 30R.